Cas no 512809-84-6 (2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide)

2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide is a heterocyclic hydrazide derivative featuring a pyrazole core with a methyl substituent at the 3-position. This compound is of interest in medicinal and agrochemical research due to its potential as a versatile intermediate for synthesizing biologically active molecules. The presence of both hydrazide and pyrazole moieties enhances its reactivity, enabling applications in the development of pharmaceuticals, such as antimicrobial or anti-inflammatory agents, and crop protection chemicals. Its structural flexibility allows for further functionalization, making it valuable in scaffold-based drug design. The compound exhibits moderate stability under standard conditions, facilitating handling in synthetic workflows. Analytical characterization is typically performed via NMR, HPLC, or LC-MS for quality assurance.
2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide structure
512809-84-6 structure
Product Name:2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide
CAS No:512809-84-6
MF:C6H10N4O
MW:154.169800281525
MDL:MFCD03419452
CID:3058757
PubChem ID:3682963
Update Time:2025-10-28

2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide Chemical and Physical Properties

Names and Identifiers

    • (3-Methyl-pyrazol-1-yl)-acetic acid hydrazide
    • 2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide
    • MDL: MFCD03419452
    • Inchi: 1S/C6H10N4O/c1-5-2-3-10(9-5)4-6(11)8-7/h2-3H,4,7H2,1H3,(H,8,11)
    • InChI Key: FEIAQNUMUGJOSO-UHFFFAOYSA-N
    • SMILES: O=C(CN1C=CC(C)=N1)NN

Computed Properties

  • Hydrogen Bond Donor Count: 2
  • Hydrogen Bond Acceptor Count: 5
  • Heavy Atom Count: 11
  • Rotatable Bond Count: 3

2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
Fluorochem
026795-1g
3-Methyl-1H-pyrazol-1-yl)acetic acid hydrazide
512809-84-6
1g
£210.00 2022-03-01
Fluorochem
026795-5g
3-Methyl-1H-pyrazol-1-yl)acetic acid hydrazide
512809-84-6
5g
£591.00 2022-03-01
TRC
M019380-100mg
2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide
512809-84-6
100mg
$ 185.00 2022-06-04
TRC
M019380-250mg
2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide
512809-84-6
250mg
$ 380.00 2022-06-04
TRC
M019380-500mg
2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide
512809-84-6
500mg
$ 600.00 2022-06-04
Chemenu
CM115081-1g
2-(3-methyl-1H-pyrazol-1-yl)acetohydrazide
512809-84-6 95%
1g
$240 2021-08-06
Chemenu
CM115081-5g
2-(3-methyl-1H-pyrazol-1-yl)acetohydrazide
512809-84-6 95%
5g
$720 2021-08-06
abcr
AB405172-250 mg
2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide
512809-84-6
250MG
€198.50 2022-03-24
abcr
AB405172-500 mg
2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide
512809-84-6
500MG
€264.80 2022-03-24
abcr
AB405172-1 g
2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide; .
512809-84-6
1 g
€406.00 2023-07-19

Additional information on 2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide

Recent Advances in the Study of 2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide (CAS: 512809-84-6)

The compound 2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide (CAS: 512809-84-6) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile pharmacological properties and potential therapeutic applications. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activities, and mechanistic insights.

Recent studies have highlighted the role of 2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide as a key intermediate in the synthesis of novel heterocyclic compounds with potential antimicrobial, anticancer, and anti-inflammatory activities. A study published in the Journal of Medicinal Chemistry (2023) demonstrated its efficacy as a scaffold for designing inhibitors targeting bacterial enzymes, particularly in drug-resistant strains. The compound's hydrazide moiety has been shown to enhance binding affinity to target proteins, making it a promising candidate for further drug development.

In addition to its antimicrobial properties, research has also explored the anticancer potential of 2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported that derivatives of this compound exhibited selective cytotoxicity against certain cancer cell lines, including breast and lung cancer, while showing minimal toxicity to normal cells. Mechanistic studies suggested that these derivatives induce apoptosis via the mitochondrial pathway, highlighting their potential as targeted anticancer agents.

The synthesis and optimization of 2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide have also been a focus of recent research. Advanced synthetic methodologies, such as microwave-assisted synthesis and green chemistry approaches, have been employed to improve yield and purity. These advancements are critical for scaling up production and ensuring reproducibility in preclinical studies.

Despite these promising findings, challenges remain in the clinical translation of 2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide-based therapeutics. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through further pharmacokinetic and pharmacodynamic studies. Collaborative efforts between academic researchers and pharmaceutical companies are essential to overcome these hurdles and advance the compound into clinical trials.

In conclusion, 2-(3-Methyl-1H-pyrazol-1-yl)acetohydrazide (CAS: 512809-84-6) represents a promising scaffold for the development of novel therapeutic agents. Its diverse biological activities and synthetic versatility make it a valuable subject of ongoing research. Future studies should focus on optimizing its pharmacological profile and exploring its potential in combination therapies to maximize therapeutic efficacy.

Recommended suppliers
Shandong Feiyang Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shandong Feiyang Chemical Co., Ltd
Shanghai Hongxiang Biomedical Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shanghai Hongxiang Biomedical Technology Co., Ltd.
Shenzhen Yaoyuan R&D Center Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shenzhen Yaoyuan R&D Center Co.,Ltd
Beyond Pharmaceutical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Hangzhou Cedareal Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Hangzhou Cedareal Technology Co., Ltd.